SOAT1 and posterior cortical atrophy: Since in an exploratory experiment nevanimibe treatment of LNCaP (Fig. S3A) and PC3 PCa cells (Fig. S3B) significantly decreased viability, a clinical trial of the available SOAT1 inhibitor nevanimibe might present a possible treatment option in high risk PCa patients with high SOAT1 expression and biochemical progression.